


Claims:

1. A compound of formula (I):



wherein:

5 R_1 is H, or C_{1-4} alkyl, halo, halo C_{1-4} alkyl, CN, C_{1-4} alkoxy, halo C_{1-4} alkoxy;

R_2 is H, C_{1-4} alkyl, C_{3-4} spiro carbocycly, halo C_{1-4} alkyl or halo;

R_3 is H, C_{1-4} alkyl, halo C_{1-4} alkyl, halo; or R_3 is absent;

R_{13} is H, C_{1-4} alkyl, halo C_{1-4} alkyl, halo; or R_{13} is absent;

10 A is a 5 or 6 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl;

X is C or N;

Y is C or N;

R_4 is C_{1-4} alkyl;


15 R_5 is H, Deuterium, C_{1-4} alkyl;

or R_4 and R_5 can be fused to form C_{3-4} spiro carbocycly;

wherein R_2 and R_3 may be attached to the same or a different ring atom; and wherein R_2 may be attached to a fused ring atom;

or a pharmaceutically acceptable salt and/or solvate thereof.

2-1. ~~A~~The compound according to claim 1, which is of formula (Ia):



wherein

R₁ is H, or C₁₋₄alkyl, halo, haloC₁₋₄alkyl, CN, C₁₋₄alkoxy, haloC₁₋₄alkoxy;

5 R₂ is H, C₁₋₄alkyl, C₃₋₄ spiro carbocycly, haloC₁₋₄alkyl or halo;

R₃ is H, C₁₋₄alkyl, haloC₁₋₄alkyl, halo;

A is a 5 or 6 membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl;

X is C or N;

10 Y is C or N;

R₄ is C₁₋₄ alkyl;

R₅ is H, Deuterium, C₁₋₄ alkyl;

or R₄ and R₅ can be fused to form C₃₋₄ spiro carbocycly;

wherein R₂ and R₃ may be attached to the same or a different ring atom;

15 and wherein R₂ may be attached to a fused ring atom;

or a pharmaceutically acceptable salt thereof.

32. The compound according to claim 1 or claim 2, wherein R₁ is H or methyl.

4. — The compound according to any one of claims 1 to 3, wherein A is a 5-membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl.

5. — The compound according to any one of claims 1 to 3, wherein A is a 6-membered saturated or unsaturated heterocycle, with at least one O atom; which heterocycle is optionally fused with a cyclopropyl group to form a tricycle when considered together with the phenyl.

6. — The compound according to any one of claims 1 to 5, wherein the ring A is dihydrofuran or dihydropyran.

73. The compound according to any one of claims 1 to 6 or claim 2, wherein R₂ is H, methyl or a C₃ spiro group.

84. The compound according to any one of claims 1 to 73, wherein R₃ is H or methyl.

9. — The compound according to any one of claims 1 to 8, wherein R₁₃ is H, F or methyl.

105. The compound according to any one of claims 1 to 94, wherein X is C and Y is C.


116. The compound according to any one of claims 1 to 94, wherein X is C and Y is N.

127. The compound according to any one of claims 1 to 49, wherein X is N and Y is N.

138. The compound according to any one of claims 1 to 127, wherein R₄ is methyl or ethyl.

149. The compound according to any one of claims 1 to 138, wherein R₅ is H or methyl.

15. — The compound according to any one of claims 1 to 14, wherein R₄ and R₅ have the stereochemical arrangement:



16. — A compound according to claim 1 selected from the group consisting of:

(5R)-3-[4-(1,3-dihydro-2-benzofuran-4-yloxy)phenyl]-5-methyl-2,4-imidazolidinedione;

(5R)-5-methyl-3-[4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-2,4-imidazolidinedione;

(5R)-3-[4-[(3,6-dimethyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-5-methyl-2,4-imidazolidinedione;

5,5-dimethyl-3-[4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-2,4-imidazolidinedione;

- (5R)-5-ethyl-3-{6-[(3-ethyl-1,2-benzisoxazol-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione;
- (5R)-5-ethyl-3-{6-[(3-(1-methylethyl)-1,2-benzisoxazol-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione;
- (5R)-3-{4-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]phenyl}-5-methyl-2,4-imidazolidinedione;
- (5R)-3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-methyl-2,4-imidazolidinedione;
- 5 {5R}-3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-2,4-imidazolidinedione;
- (5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-ethyl-2,4-imidazolidinedione;
- 7-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5,7-diazaspiro[3.4]octane-6,8-dione;
- 6-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-4,6-diazaspiro[2.4]heptane-5,7-dione;
- 3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione;
- 10 {5R}-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-(1,1-dimethylethyl)-2,4-imidazolidinedione;
- (5R)-5-ethyl-3-{6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl}-2,4-imidazolidinedione;
- 5,5-dimethyl-3-{6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl}-2,4-imidazolidinedione;
- (5R)-5-ethyl-5-methyl-3-{6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl}-2,4-
- 15 imidazolidinedione;
- (5R)-5-ethyl-3-{6-[(3S/R)-3-methyl-1,3-dihydro-2-benzofuran-4-yl]oxy}-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomeric mixture);
- (5R)-5-ethyl-3-{6-[(3-methyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomers 1 and 2);
- 20 {5R}-5-ethyl-3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (distereoisomeric mixture);
- (5R)-5-ethyl-3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomers 1 and 2);
- 5,5-dimethyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemic mixture);
- 25 5,5-dimethyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (enantiomers 1 and enantiomer 2);
- 5,5-dimethyl-3-{6-[(1a-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemic mixture);

- 5,5-dimethyl-3-{6-[(1a-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (enantiomer 1 and enantiomer 2);
- {5R}-5-ethyl-5-methyl-3-[6-(1H-spiro[2-benzopyran-4,1'-cyclopropan]-5-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- 5 3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5,5-dimethyl-2,4-imidazolidinedione;
- {5R}-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-(1-methylethyl)-2,4-imidazolidinedione;
- {5R}-3-{6-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-2,4-imidazolidinedione;
- 5,5-dimethyl-3-[6-(1H-spiro[2-benzopyran-4,1'-cyclopropan]-5-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- 10 {5R}-3-[2-(2,3-dihydrospiro[chromene-4,1'-cyclopropan]-5-yloxy)-5-pyrimidinyl]-5-ethyl-5-methyl-2,4-imidazolidinedione;
- 5,5-dimethyl-3-{6-[(4-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemate mixture, enantiomer 1, enantiomer 2);
- {5R}-5-ethyl-5-methyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione
- 15 {diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2};
- {5R}-5-ethyl-5-methyl-3-[6-(1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yloxy)-3-pyridinyl]-2,4-imidazolidinedione (diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2);
- 3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione (racemate mixture, enantiomer 1, enantiomer 2);
- 20 {5R}-5-ethyl-5-methyl-3-[2-(4-methylchroman-5-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione
- {diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2};
- {5R}-5-ethyl-5-methyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;
- {5R}-3-[2-(3,3-dimethylisochroman-5-yl)oxypyrimidin-5-yl]-5-ethyl-5-methyl-imidazolidine-2,4-dione;
- 25 {5R}-5-ethyl-5-methyl-3-[2-(7-methylspiro[1H-isobenzofuran-3,1'-cyclobutane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;
- {5R}-5-ethyl-5-methyl-3-{2-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-2,4-imidazolidinedione;
- {5R}-3-{2-[(2,2-difluoro-7-methyl-1,3-benzodioxol-4-yl)oxy]-5-pyrimidinyl}-5-ethyl-5-methyl-2,4-
- 30 imidazolidinedione;

~~(5R)-3-[2-[(2,2-difluoro-1,3-benzodioxol-4-yl)oxy]-5-pyrimidinyl]-5-ethyl-5-methyl-2,4-imidazolidinedione;~~

~~(5R)-5-ethyl-5-methyl-3-[2-[(2,4,4-trimethyl-4H-3,1-benzoxazin-5-yl)oxy]-5-pyrimidinyl]-2,4-imidazolidinedione;~~

5 ~~5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;~~

~~3-[2-(3,3-dimethylisochroman-5-yl)oxypyrimidin-5-yl]-5,5-dimethyl-imidazolidine-2,4-dione;~~

~~5,5-dimethyl-3-[2-(7-methylspiro[1H-isobenzofuran-3,1'-cyclobutane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;~~

10 ~~(5R)-5-ethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione;~~

~~(5R)-5-ethyl-3-[6-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione;~~

~~(5R)-5-ethyl-3-[6-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl]-2,4-imidazolidinedione;~~

~~(5R)-5-ethyl-3-[2-[(3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl]-2,4-imidazolidinedione;~~

15 ~~(5R)-5-ethyl-5-methyl-3-[6-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione;~~

~~(5R)-3-[6-(3,3-dimethylisochroman-5-yl)oxy-3-pyridyl]-5-ethyl-5-methyl-imidazolidine-2,4-dione;~~

~~(5R)-3-[6-[(3,3-diethyl-1H-isobenzofuran-4-yl)oxy]-3-pyridyl]-5-ethyl-5-methyl-imidazolidine-2,4-dione;~~

~~(5R)-5-ethyl-5-methyl-3-[6-[(2,4,4-trimethyl-3,1-benzoxazin-5-yl)oxy]-3-pyridyl]imidazolidine-2,4-dione;~~

20 ~~(5R)-3-[6-[(3,3-dimethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl]-5-ethyl-5-methyl-2,4-imidazolidinedione; and~~

~~5,5-dimethyl-3-[6-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxy-3-pyridyl]imidazolidine-2,4-dione.~~

~~1710.~~ The compound according to claim 16, selected from the group consisting of:

25 (5R)-3-[4-(1,3-dihydro-2-benzofuran-4-yloxy)phenyl]-5-methyl-2,4-imidazolidinedione;

(5R)-5-methyl-3-[4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-2,4-imidazolidinedione;

(5R)-3-[4-[(3,6-dimethyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-5-methyl-2,4-imidazolidinedione;

5,5-dimethyl-3-[4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl]-2,4-imidazolidinedione;

(5R)-5-ethyl-3-[6-[(3-ethyl-1,2-benzisoxazol-4-yl)oxy]-3-pyridinyl]-2,4-imidazolidinedione;

30

- (5R)-5-ethyl-3-(6-([3-(1-methylethyl)-1,2-benzisoxazol-4-yl]oxy)-3-pyridinyl)-2,4-imidazolidinedione;
- (5R)-3-{4-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]phenyl}-5-methyl-2,4-imidazolidinedione;
- (5R)-3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-methyl-2,4-imidazolidinedione;
- (5R)-3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-2,4-imidazolidinedione;
- 5 (5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-ethyl-2,4-imidazolidinedione;
- 7-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5,7-diazaspiro[3.4]octane-6,8-dione;
- 6-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-4,6-diazaspiro[2.4]heptane-5,7-dione;
- 3-{6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione;
- (5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-(1,1-dimethylethyl)-2,4-
- 10 imidazolidinedione;
- (5R)-5-ethyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- 5,5-dimethyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;
- (5R)-5-ethyl-5-methyl-3-[6-(spiro[1-benzofuran-3,1'-cyclopropan]-4-yloxy)-3-pyridinyl]-2,4-
- imidazolidinedione;
- 15 (5R)-5-ethyl-3-(6-([(3S/R)-3-methyl-1,3-dihydro-2-benzofuran-4-yl]oxy)-3-pyridinyl)-2,4-imidazolidinedione (diastereoisomeric mixture);
- (5R)-5-ethyl-3-{6-[(3-methyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomers 1 and 2);
- (5R)-5-ethyl-3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione
- 20 (distereoisomeric mixture);
- (5R)-5-ethyl-3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomers 1 and 2);
- 5,5-dimethyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemic mixture);
- 25 5,5-dimethyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (enantiomers 1 and enantiomer 2);
- 5,5-dimethyl-3-{6-[(1a-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemic mixture);

5,5-dimethyl-3-{6-[(1a-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (enantiomer 1 and enantiomer 2);

(5R)-5-ethyl-5-methyl-3-[6-(1H-spiro[2-benzopyran-4,1'-cyclopropan]-5-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;

5 3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5,5-dimethyl-2,4-imidazolidinedione;

(5R)-3-{2-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-5-pyrimidinyl}-5-(1-methylethyl)-2,4-imidazolidinedione;

(5R)-3-{6-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-3-pyridinyl}-5-ethyl-2,4-imidazolidinedione;

5,5-dimethyl-3-[6-(1H-spiro[2-benzopyran-4,1'-cyclopropan]-5-yloxy)-3-pyridinyl]-2,4-imidazolidinedione;

10 (5R)-3-[2-(2,3-dihydrospiro[chromene-4,1'-cyclopropan]-5-yloxy)-5-pyrimidinyl]-5-ethyl-5-methyl-2,4-imidazolidinedione;

5,5-dimethyl-3-{6-[(4-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (racemate mixture, enantiomer 1, enantiomer 2);

15 (5R)-5-ethyl-5-methyl-3-{6-[(3-methyl-3,4-dihydro-2H-chromen-5-yl)oxy]-3-pyridinyl}-2,4-imidazolidinedione (diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2);

(5R)-5-ethyl-5-methyl-3-[6-(1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yloxy)-3-pyridinyl]-2,4-imidazolidinedione (diastereoisomeric mixture, diastereoisomer 1, diastereoisomer 2); and

3-{6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione (racemate mixture, enantiomer 1, enantiomer 2).

20 ~~1811~~. Use of a compound according to any one of claims 1 to ~~17~~10 in the manufacture of a medicament for the prophylaxis or treatment of hearing disorders, schizophrenia, bipolar disorder or sleep disorders.

~~1912~~. The use according to claim ~~18-11~~ in manufacture of a medicament for the the prophylaxis or treatment of hearing disorders.

25 ~~2013~~. The use according to claim ~~18-11~~ or claim ~~1912~~, wherein the hearing disorder is selected from the group consisting of auditory neuropathy, auditory processing disorder, hearing loss, which includes sudden hearing loss, noise induced hearing loss, substance-induced hearing loss, hearing loss in adults over 60 (presbycusis), and tinnitus.

~~2114~~. The use according to claim ~~18-11~~ or claim ~~1912~~, wherein the hearing disorder is hearing loss.


~~2215~~. The use according to claim ~~18-11~~ or claim ~~1912~~, wherein the hearing disorder is tinnitus.

~~23~~16. The use according to claim ~~11~~18, in the manufacture of a medicament for the prophylaxis or treatment of schizophrenia.


~~24~~17. A pharmaceutical composition comprising a compound according to any one of claims 1 to ~~17~~10 and a pharmaceutically acceptable carrier or excipient.

5 ~~25~~18. A compound selected from:

spiro[1-benzofuran-3,1'-cyclopropan]-4-ol




7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-ol




; and

10 3,3,7-trimethyl-2,3-dihydro-1-benzofuran-4-ol



or a salt thereof.

~~26.~~ A compound selected from:




15 wherein:

X is C or N;

Y is C or N; and

the group W is selected from:






7

or a salt thereof.

19. A compound which is selected from the group consisting of:

5



10

or a salt thereof.